Introduction {#S0001}
============

Noninvasive ventilation (NIV) is the standard therapy for ventilatory failure in acute exacerbation of COPD. Increasing evidence of its effectiveness has been generated for more than two decades.[@CIT0001] Studies have demonstrated a rapid improvement in blood gases as well as the reduction of respiratory rate, frequency of intubation, length of hospital stay, and mortality.[@CIT0002]

Recent trials have shown that NIV also benefits COPD patients with chronic hypercapnia.[@CIT0003]--[@CIT0005] A multi-center study with 195 stable hypercapnic COPD patients revealed that NIV decreases 1-year mortality.[@CIT0003] A further study confirmed reduced mortality and additionally showed reduced rates of exacerbation and hospital readmission.[@CIT0004] Other parameters improved by NIV include hypercapnia, oxygen saturation, respiratory rate, dyspnea, 6-min walking test (6MWT)-distance, and quality of life (QoL).[@CIT0003],[@CIT0005]--[@CIT0010] Despite these encouraging results, it is also evident that some patients do not tolerate NIV or do not benefit from it.[@CIT0009],[@CIT0011]--[@CIT0013]

Nasal high-flow (NHF) provides warmed and humidified gas administered through slightly enlarged nasal prongs. Oxygen fraction can be adjusted according to clinical requirements. Near-saturated humidity and gas warmed to body temperature allow tolerance of high flow rates. NHF results in only small increases of airway pressure, further reduced by opening the mouth.[@CIT0014] NHF reduces minute volume, lowers respiratory rate, and decreases work of breathing.[@CIT0015]--[@CIT0018] The exhaled gas in the upper airways is rapidly washed out, and thus physiological dead-space is reduced.[@CIT0019],[@CIT0020] The high flow rates delivered by NHF are sufficient to cover even high peak inspiratory flows, thereby avoiding the admixture of ambient air.[@CIT0021]

In a recent study, NHF was found to be superior to standard nasal prongs (SNP) and NIV in patients with severe hypoxemic respiratory failure with regard to intubation rate and mortality.[@CIT0022] Reintubation rates with NHF were lower than[@CIT0023],[@CIT0024] or non-inferior[@CIT0025] compared to either venturi mask, SNP or NIV, respectively.

In addition, there is mounting evidence that NHF leads to a reduction in partial pressure of CO~2~ (pCO~2~) reduction in hypercapnic patients over short periods.[@CIT0015],[@CIT0026]--[@CIT0029] NHF was also successful in reducing pCO~2~ in a small pilot trial for 6 weeks.[@CIT0027] Together with CO~2~ wash-out studies[@CIT0019],[@CIT0027] these results led us to hypothesize that NHF might benefit chronic hypercapnic COPD patients.

To test this hypothesis, we conducted a study in which COPD patients with stable, chronic hypercapnia were treated in a cross-over design with NIV and NHF for 6 weeks each. The primary endpoint was pCO~2~ reduction compared to baseline.

Materials and methods {#S0002}
=====================

Study subjects {#S0002-S2001}
--------------

COPD patients with chronic respiratory insufficiency and stable daytime hypercapnia (pCO~2~≥50 mmHg) were recruited from 13 hospitals in Germany. Patients were excluded if they had a type I or II exacerbation[@CIT0030] within the last 4 weeks, had been treated with NIV during the last 14 days, or if their body mass index was higher than 30 kg/m^2^. The full list of inclusion and exclusion criteria can be found in the [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx) (section 2). All patients were at least 18 years of age and provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki. Local institutional review boards or independent ethics committees approved the protocol, and written informed consent was obtained from all patients (Ethical Committee at the Medical Faculty, Leipzig University 123/09-ff). The trial registered with clinicaltrials.gov (NCT02007772).

Study design {#S0002-S2002}
------------

NHF and NIV were compared in a multi-centered, randomized, controlled, 12-week cross-over trial (randomized controlled trial; RCT) (6 weeks with each device, see [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx) \[section 1\]). The primary goal was to provide an estimate of the difference between the devices regarding pCO~2~ change.

Methods {#S0002-S2003}
-------

Patients were randomly assigned to receive either NHF or NIV first. Randomization was performed centrally by the Clinical Trial Center Leipzig using block randomization with variable block length, stratified by trial site.

For NHF, we used the TNI 20 oxy and nasal prongs with medium bore outlets (TNI Medical AG, Wuerzburg, Germany). A flow rate of 20 L/min was stipulated by the study protocol and oxygen supplementation was not changed compared to baseline (spontaneous breathing with oxygen by nasal cannula). At the time of study inception, NHF devices did not delivered \>20 L/min.

All centers were instructed to follow the German guidelines for humidification and NIV pressure settings. It was the general aim to adjust pressures to achieve optimal tolerability and pCO~2~ reduction.[@CIT0031] The preferred interface was an oronasal mask, but a nasal mask could be used in case of intolerance. Trial sites were free to choose their preferred NIV (listed in [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx)).

Patients were advised to use NIV and NHF for at least 6 hrs per day, preferably during sleep, but usage in the daytime was also accepted. Duration of ventilation was based on the devices\' usage data.

Analysis {#S0002-S2004}
--------

The primary endpoint was the change in pCO~2~ between baseline and the end of the NIV or NHF treatment. The secondary endpoints were changes in capillary blood gases, lung function, 6MWT, QoL and compliance (see [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx) \[section 4\]).

The rationale that motivated this trial was intrinsically the non-inferiority of NHF. Because of the paucity of data and lack of consensus regarding margins of equivalence in this context, we chose descriptive estimates for the primary analysis and a non-inferiority test as a secondary analysis. The sample size determination followed accordingly. Based on an expected SD of 11% in paired differences taken from pilot data, a sample size of 70 patients was required to have a 95% CI spanning a width of 6% of the baseline value (difference in paired means, coverage corrected, nQuery 6.02). Taking drop-out into account, a recruitment of 100 patients was planned for this study. A test of non-inferiority of NHF with a margin of 5 mm Hg was specified in the statistical plan as a secondary analysis, based on mean treatment effects from two trials available at the time.[@CIT0003],[@CIT0032]

The full analysis set (intention to treat) included all patients who started treatment and had pCO~2~ values ≥50 mm Hg at screening and no \<45 mm Hg at baseline. The per protocol set includes essentially those patients that received both devices and used them sufficiently (see [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx) \[section 3\] for a precise definition).

Missing data were accounted for using multiple imputation (see [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx) \[section 4\]). Outcomes were analyzed with a mixed model for repeated measures with the patient as a random variable. The difference between NHF and NIV devices was estimated along with a 95% CI. In one sensitivity analysis, the same mixed model was applied to non-imputed data. In a second sensitivity analysis, the trial center was included as a random term. A paired *t*-test was used to compare the duration of device usage. For data analysis and graphic presentation, we used the software package R (version 3.4.1).

Results {#S0003}
=======

Patients {#S0003-S2001}
--------

From May 2011 until November 2016, 102 patients were randomized, 94 of whom were included in the intention to treat analysis ([Figure 1](#F0001){ref-type="fig"}). Since the pCO~2~ levels of five randomized patients (pCO~2~≥50 mmHg at screening) decreased to below 45 mmHg at baseline, the indication for treatment was no longer given. Three further patients withdrew from the trial before receiving the first treatment.Figure 1Flowchart of enrolment, device usage and patients analyzed.**Abbreviations:** NHF, nasal high-flow; NIV, noninvasive ventilation; PCO~2~, the partial pressure of carbon dioxide in capillary blood.

The per protocol set contained 53 patients with similar demographic characteristics and baseline pCO~2~ values to the full analysis set. Baseline characteristics are presented in [Table 1](#T0001){ref-type="table"}, and list of concomitant diseases and medications can be found in [Tables S2](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx) and [S3](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx). All patients had no history of any lasting NIV treatment, but all were on long-term oxygen therapy.Table 1Baseline demographic and clinical characteristicsN=94Females57 (61%)Age (years)65.3±9.3BMI (kg/m^2^)23.1±4.8 BMI \<18.520 (21%) 18.5 ≤ BMI \<2537 (39%) BMI ≥2537 (39%)Heart rate (bpm)82.3±12.9Six-minute walking test (m)236±135Time since COPD diagnosis (years)7.1 (3.3 to 11.7)Smoking Current smoker19 (21%) Ex-smoker69 (77%) Never smoked2 (2%)Number of pack years40 (28 to 51)Number of exacerbations in last 12 months^a^1.8±2.2 0 exacerbations24 (26%) 1--2 exacerbations46 (51%) ≥3 exacerbations21 (23%) Number with hospital stay1.2±1.6CAT score24.7±7.6GOLD classification 2011  D79 (90%)  C6 (7%)  B or A3 (3%)O~2~ insufflation (L/min)2.0±0.9Capillary pCO~2~ (mmHg)56.5±5.4Capillary pO~2~ (mmHg)68.9±16.0pH7.399±0.036Base excess (BE, mmol/L)8.4±3.8HCO~3~^−^ (mmol/L)32.1±3.2FEV~1~ (% predicted)28.5±10.2FVC (% predicted)48.0±15.0FEV~1~/FVC (%)49.4±13.4Respiratory rate (breaths/min)20.7±5.5[^1][^2]

Treatments {#S0003-S2002}
----------

A total of 91 patients began NHF treatment with a flow rate of 19.8±0.6 L/min and O~2~ insufflation of 2.2±0.9 L/min and 82 patients began NIV treatment with an oronasal mask (57), with a nasal mask (21), or with both (1). Three patients did not tolerate NIV very early on and terminated use within the first 24 hrs. An additional 11 patients terminated use of NIV early, six for device related, four for disease-related and one for study-related reasons. Sixteen patients terminated use of NHF early, six for device related, five for disease-related and five for study-related reasons. Mean inspiratory and expiratory positive airway pressures (IPAP and EPAP) were 20.5±3.6 cm H~2~O and 4.6±1.2 cm H~2~O respectively, O~2~ rate was 2.0±0.7 L/min and 13.3±3.9 breaths/min for those in S/T mode (n=73).

Data on time used were available for 70 NHF devices (77%), 54 NIV devices (66%), and for 47 patients who used both. Mean duration of NHF usage was 5.2±3.3 hrs/day compared to 3.9±2.5 hrs/day for NIV. The mean difference for those who used both was 1.6 hrs/day (95% CI, 0.9--2.4; *P*\<0.001) for NHF versus NIV ([Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx)).

Primary and secondary endpoints {#S0003-S2003}
-------------------------------

PCO~2~ levels decreased by 2.8 mm Hg (95% CI 1.1--4.6) or 4.7% (95% CI 1.8--7.5) using NHF and 4.2 mm Hg (95% CI 2.4--6.0) or 7.1% (95% CI 4.1--10.1) from baseline using NIV. The difference of pCO~2~ changes between the two devices was −1.4 mmHg (95% CI −3.1--0.4), where the minus sign indicates that NIV had a stronger effect ([Table 2](#T0002){ref-type="table"}). This difference lies within the non-inferiority margin of 5 mm Hg, *P*\<0.001. Sensitivity analyses demonstrated that neither a completer case analysis nor the introduction of a random effect from the centers alters this result meaningfully. In the per protocol set, pCO~2~ levels decreased by 2.9 mmHg and 4.3 mmHg using NHF and NIV, respectively, and the difference of pCO~2~ changes between the devices was −1.3 (95% CI −3.0--0.4) mmHg and thus indistinguishable from that of the full analysis set. There was no indication that the order of devices was relevant (*P*=0.59). Blood samples were taken a median of 7.0 hrs (IQR: 4.6--8.7) after stopping use of the device.Table 2Primary and secondary outcomesBaselineChange using NHF*P*-value\
(NHF)Change using NIV*P*-value\
(NIV)Difference in changebetween NHF and NIV*P*-value\
(NHF vs NIV)**Basic physiological parameters** Respiratory rate (breaths/min)20.3−1.4 (−2.9 to −0.0)**0.046**−0.1 (−1.6 to 1.3)0.841.3 (−0.1 to 2.7)0.076 Heart rate (beats/min)82.02.0 (−2.0 to 6.0)0.335.0 (1.0 to 9.0)**0.015**3.0 (−1.1 to 7.1)0.15**Blood gas analysis** pCO~2~ (mm Hg)56.5−2.8 (−4.6 to −1.1)**0.0020**−4.2 (−6.0 to −2.4)**\<0.001**−1.4 (−3.1 to 0.4)0.12 pO~2~ (mm Hg)68.91.4 (−3.1 to 6.0)0.530.8 (−3.8 to 5.3)0.74−0.7 (−5.3 to 3.9)0.77 SaO~2~ (%)93.70.3 (−0.7 to 1.4)0.530.0 (−1.1 to 1.1)0.98−0.3 (−1.4 to 0.8)0.55 Base excess (mmol/L)8.4−1.5 (−2.2 to −0.7)**\<0.001**−2.0 (−2.7 to −1.3)**\<0.001**−0.5 (−1.2 to 0.2)0.14 HCO~3~^−^ (mmol/L)32.1−1.5 (−2.2 to −0.8)**\<0.001**−2.2 (−2.9 to −1.5)**\<0.001**−0.7 (−1.4 to 0.0)0.056 pH7.40−0.00 (−0.01 to 0.01)0.990.01 (−0.01 to 0.01)0.590.00 (−0.01 to 0.01)0.86**Spirometry** FVC (% predicted)47.90.8 (−2.1 to 3.7)0.582.3 (−0.6 to 5.2)0.121.5 (−1.2 to 4.2)0.28 FEV1 (% predicted)28.41.1 (−0.6 to 2.8)0.212.0 (0.2 to 3.7)**0.027**0.9 (−0.8 to 2.5)0.30 FEV1/FVC (%)50.10.9 (−2.2 to 3.9)0.571.2 (−1.8 to 4.2)0.430.3 (−2.6 to 3.3)0.42 R~tot~ (% predicted)^a^301.71.10 (0.99 to 1.22)0.0640.98 (0.89 to 1.09)0.720.89 (0.80 to 0.99)**0.033** RV (% predicted)244.2−2.3 (−19.0 to 14.4)0.791.8 (−14.9 to 18.5)0.834.1 (−12.7 to 20.9)0.63 RV/TLC (% predicted)181.2−0.6 (−7.3 to 6.2)0.862.9 (−3.9 to 9.6)0.403.5 (−3.4 to 10.3)0.32**Respiratory muscle assessment** P~0.1~ (% predicted)^a^279.61.06 (0.95 to 1.19)0.311.03 (0.91 to 1.15)0.650.97 (0.87 to 1.08)0.53 PI~max~ (% predicted)37.10.0 (−3.2 to 3.2)0.982.3 (−0.9 to 5.5)0.162.2 (−0.8 to 5.2)0.14**Six-minute walking test (m)**233.015.2 (−4.8 to 35.2)0.1425.5 (5.5 to 45.5)**0.013**10.3 (−10.0 to 30.6)0.31**SRI** Respiratory Complaints43.83.9 (0.7 to 7.2)**0.018**2.8 (−0.4 to 6.1)0.085−1.1 (−4.3 to 2.1)0.50 Physical Functioning32.15.0 (1.0 to 9.0)**0.015**4.8 (0.8 to 8.8)**0.020**−0.2 (−4.2 to 3.8)0.92 Attendant Symptoms and Sleep54.67.5 (3.1 to 11.9)**0.0010**5.1 (0.7 to 9.5)**0.024**−2.4 (−6.8 to 2.0)0.28 Social Relationships67.91.5 (−2.8 to 5.9)0.48−0.4 (−4.8 to 3.9)0.85−1.9 (−6.3 to 2.4)0.37 Anxiety54.42.7 (−2.0 to 7.4)0.264.0 (−0.7 to 8.7)0.0921.3 (−3.3 to 6.0)0.57 Psychological Well-Being53.13.0 (−0.3 to 6.3)0.0783.7 (0.4 to 7.1)**0.027**0.8 (−2.5 to 4.1)0.65 Social Functioning47.61.3 (−2.2 to 4.9)0.461.5 (−2.1 to 5.0)0.410.2 (−3.4 to 3.7)0.93 Summary Scale50.63.5 (1.1 to 5.8)**0.0039**2.7 (0.3 to 5.0)**0.025**−0.8 (−3.1 to 1.5)0.50**SGRQ**Symptoms72.7−11.9 (−17.2 to −6.6)**\<0.001**−11.6 (−16.9 to −6.3)**\<0.001**0.3 (−5.0 to 5.6)0.92Activity84.5−4.4 (−7.8 to −1.0)**0.011**−4.2 (−7.6 to −0.9)**0.014**0.2 (−3.2 to 3.5)0.92Impacts57.3−5.8 (−9.7 to −2.0)**0.0035**−6.5 (−10.3 to −2.6)**0.0011**−0.7 (−4.5 to 3.1)0.72Total68.1−6.2 (−8.9 to −3.5)**\<0.001**−6.9 (−9.6 to −4.2)**\<0.001**−0.7 (−3.4 to 2.0)0.62**Modified Borg Scale**Before 6 min walk4.4−0.2 (−0.8 to 0.4)0.45−0.2 (−0.8 to 0.4)0.470.0 (−0.6 to 0.6)0.96After 6 min walk5.9−0.3 (−0.9 to 0.4)0.39−0.4 (−1.0 to 0.2)0.19−0.1 (−0.8 to 0.5)0.65**VAS regarding state of health**3.71.0 (0.2 to 1.8)0.0150.9 (0.1 to 1.7)0.027−0.1 (−0.9 to 0.7)0.81**Assessment of Devices**------−0.2 (−0.4 to 0.2)0.29[^3][^4]

A considerable reduction in pCO~2~ (\>5 mm Hg) was reached in 37% of patients during NHF use and 52% during NIV use. However, increases in pCO~2~ were observed in 26% with NHF and 22% with NIV ([Figure 2](#F0002){ref-type="fig"}). An exploratory analysis of reasons for good/poor response can be found in section 5 of the [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx).Figure 2Waterfall plot depicting the individual change in carbon dioxide levels in capillary blood (pCO~2~) before and after intervention.**Notes:** NHF, nasal high-flow; NIV, noninvasive ventilation. ΔpCO~2~ is the difference in partial pressures of carbon dioxide in capillary blood between baseline and follow-up. Each bar represents ΔpCO~2~ for a single patient and the grey lines show how the patients in the upper and lower halves correspond, ie, the grey line connects a given patient before and after cross-over. The correlation coefficient between changes with NHF and NIV (95% CI) is shown for patients that used both devices.

PO~2~, spirometry, 6MWT, and QoL are listed in [Table 2](#T0002){ref-type="table"}. Changes from baseline tended to be small for pO~2~, spirometry, and 6MWT, but were significant and clinically meaningful for QoL. While using NHF, 61% of patients improved their St. George's Respiratory Questionnairetotal scores by at least 4 points and a similar 54% while using NIV. Differences in the endpoints listed in [Table 2](#T0002){ref-type="table"} were not generally significant between NHF and NIV.

Safety {#S0003-S2004}
------

Four patients died during the trial, two while using NHF and two while using NIV (see [Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206111.docx) \[section 7\]). Other adverse events are listed according to the device used upon onset of the event in [Table 3](#T0003){ref-type="table"}.Table 3There were a total of 38 non-lethal SAEs among 21 patients (9 only NHF, 8 only NIV, 4 patients with both devices)NHFNIV**Death**22**Number of SAEs (non-lethal)**1721RespiratoryDyspnoea--1Exacerbation117Atelectasis1--Hypercapnic respiratory failure1--Mechanical ventilation11Pneumonia--1Pneumothorax spontaneous--1Pulmonary failure--1Respiratory acidosis1--CardiacMyocardial infarction1--Decompensation11Panic attack2Other--7**Number of AEs (not also SAEs)**3355Respiratory/possibly related to deviceAerophagia--5Bronchitis acute1--Claustrophobia--1Coldness local--1Conjunctivitis--1COPD exacerbation1313Dyspnoea--3Ear problem--1Epistaxis/nasal dryness/nasal irritation52Hemoptysis1--Insomnia11Middle ear disorder1--Oral thrush11Panic attacks11Rib pain1--CardiacDecompensation--1Tachycardia--1Signs of right-heart failure47Other416[^5]

Discussion {#S0004}
==========

In this randomized, controlled, multi-centered cross-over trial, NHF was similarly effective to NIV with modest improvements in capillary pCO~2~ in both groups and a slight tendency in favor of NIV. This is the first RCT providing evidence that NHF is effective in COPD patients with stable chronic hypercapnia.

NHF and NIV reduced capillary pCO~2~ by 2.8 mmHg (4.7%) and 4.2 mmHg (7.1%), respectively. These results for NIV correspond well to those of Köhnlein et al,[@CIT0003] who found that capillary pCO~2~ was lowered by 7.4% after 1 year of treatment and differed by 5.1% from the control group. A recent trial by Murphy et al[@CIT0004] observed similar reductions in pCO~2~ by 6.2 mmHg after 6 weeks.

Most studies on NHF have either excluded hypercapnic patients or studied a population containing both normo- and hypercapnic patients and have thus found little or no reduction in pCO~2~.[@CIT0023]--[@CIT0025],[@CIT0033] Studies exploring the effect of NHF on pCO~2~ in purely hypercapnic patients[@CIT0015],[@CIT0016],[@CIT0026]--[@CIT0028],[@CIT0034] suggest a dependence on the baseline pCO~2~ value, as might be expected.[@CIT0016],[@CIT0034]

A recent study compared long-term oxygen therapy (LTOT) with and without NHF in 29 stable hypercapnic COPD patients. NHF inhibited the LTOT-induced increase in pCO~2~ and improved QoL.[@CIT0035] Another recent study demonstrated unaltered lung function in COPD patients during brief NHF use.[@CIT0029]

In most studies with hypercapnic patients, blood gas samples were taken during NHF treatment or immediately thereafter.[@CIT0015],[@CIT0016],[@CIT0026],[@CIT0027] In this trial, blood gases were taken after a minimum of 3 hrs following respiratory support to a) reflect the situation in an outpatient clinic and b) provide data on lasting effects. However, this lag period might result in smaller treatment effects compared to studies with shorter intervals.[@CIT0016],[@CIT0027] In a previous, similarly designed pilot study, but without similar delay, we observed a more pronounced pCO~2~ reduction both with NHF and NIV.[@CIT0027] It is plausible that pCO~2~ rises during the day after night-time use of respiratory support. The mentioned NIV trials on chronic hypercapnic COPD patients were designed with a 1-hr delay between NIV use and blood gas analysis.[@CIT0003],[@CIT0004]

Changes in secondary endpoints were very similar between the two devices and suggest effective respiratory support for COPD patients. In particular, improvements in QoL, a well-established benefit of NIV,[@CIT0009] were comparable with those of NHF treatment. The respiratory rate was reduced in NHF only. The 6MWT-distance increased with both devices although this was not significant for NHF. Changes in exacerbation rates and re-hospitalizations could not be assessed within the 6-week time frame. We present individual patient data on capillary pCO~2~ as a waterfall plot, demonstrating the large variance in individual response and providing data on the numbers who respond well and poorly. A similar spectrum of responses has not yet been described in a comparably clear fashion, although it has been mentioned in the literature.[@CIT0003],[@CIT0004],[@CIT0011],[@CIT0012],[@CIT0035] The SD we observed for pCO~2~ changes is roughly comparable to that reported in other studies, suggesting that they observed a similar spectrum of responses.

Many clinicians would agree that not every patient will benefit from NIV. However, there are only few dependable criteria for predicting success.[@CIT0003],[@CIT0004],[@CIT0011]--[@CIT0013],[@CIT0016],[@CIT0032] We found non-responders in roughly comparable numbers using both devices. Exploratory analyses showed that a variety of demographic and disease-specific markers were not associated with the extent of the pCO2 response. A non-negligible minority of patients had higher levels of pCO~2~ with ventilatory support compared to the beginning of the study. Such responses might derive from the fact that we performed a "real life" study in which the health of chronically ill patients can deteriorate despite the use of noninvasive respiratory support.

It is important to note that in this study, NHF was administered with a relatively moderate flow of 20 L/min, which was state of the art at trial conception. This trial demonstrates that NHF with a flow of 20 L/min is a good treatment option in stable hypercapnic COPD patients. However, it is likely that treatment with higher flow rates will result in further improvements.[@CIT0016],[@CIT0027]

An important prerequisite for an effective treatment of COPD patients by NIV is the choice of a sufficient pressure difference combined with respiratory rate control and adequate duration of treatment.[@CIT0003]--[@CIT0005],[@CIT0036] In this regard, the settings applied in our trial are slightly different from those applied in the studies of Murphy et al (median IPAP 24 cmH~2~O, EPAP 4 cm H~2~O, respiratory rate 14/min) and Köhnlein et al (mean IPAP 21.6 cmH~2~O, EPAP 4.8 cmH~2~O, respiratory rate 16/min).[@CIT0003],[@CIT0004] In our trial, NHF and NIV were used on average for 5.2 hrs/day (data available from 77% of patients) and 3.9 hrs/day (66% of patients), respectively. In the study of Köhnlein et al, NIV was used for 5.9 hrs/day (47% of patients). Murphy et al reported a mean use of 4.7 hrs/day (84% of patients) after comparable 6 weeks. When compared to NIV, the longer use of NHF observed in our trial might indicate better tolerance. A number of studies have indeed demonstrated improved comfort of NHF over other devices.[@CIT0016],[@CIT0023],[@CIT0037]

Earlier studies indicated that NIV is effective at reducing pCO~2~ only in patients with stable hypercapnia.[@CIT0003],[@CIT0004],[@CIT0032] In particular, hypercapnia can even be reversible after acute exacerbation[@CIT0032],[@CIT0038] and it is uncertain whether or not NIV then has any added benefit. Our minimum 4-week exacerbation-free interval was chosen to exclude transient hypercapnia at the time of inclusion in the study.

Limitations of our study include lower usage times of NIV, slightly lower pressure difference (IPAP-EPAP) compared to previous studies[@CIT0003],[@CIT0004] and the use of an NHF device with a restriction of 20 L/min flow. This may have influenced the efficacy of the devices. Moreover, the trial was registered after about one-quarter of the patients had been recruited, the data for usage time were incomplete and blinding was not possible. Strengths of this study are the cross over design, the demonstration of a lasting effect and the exclusion of patients with transient hypercapnia following exacerbation.

In summary, we have shown that NHF may well represent an alternative to NIV in chronic hypercapnic COPD patients with comparable effectiveness. Future studies will have to elucidate the question of how pCO2 reduction may translate into a benefit on survival or other clinical outcomes.

This study was an investigator-initiated project supported by TNI Medical AG through grants and provision of equipment. The sponsor had no role in the design and conduct of the study, the collection, management, analysis and interpretation of the data, the preparation, review or approval of the manuscript, or the decision to submit the manuscript.
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(p)CO~2~, (partial) pressure of carbon dioxide; (p)O~2,~ (partial) pressure of oxygen; 6MWT, 6-min walking test; EPAP, expiratory positive airway pressure; IPAP, inspiratory positive airway pressure; LTOT, long-term oxygen therapy; NHF, nasal high-flow; NIV, noninvasive ventilation; QoL, quality of life; RCT, randomized controlled trial; SNP, standard nasal prongs.
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[^1]: **Notes:** Values are numbers (%), mean SD or median (interquartile range). ^a^Data were unavailable for 3 patients.

[^2]: **Abbreviation:** BMI, body mass index.

[^3]: **Notes:** Numbers in brackets are 95% CI. ^a^These "changes" columns refer to an n-fold change with respect to baseline, ie, the baseline value of R~tot~ is 301.7% of the predicted value, and using NHF it changed 1.10-fold. The final column is a ratio of the two changes. The analyses in this table are based on imputation meaning the full-analysis set (n=94) was used. For SRI and SGRQ, one of the trial centers did not distribute the questionnaires so that n=80. Bold values are representative of p\<0.05.

[^4]: **Abbreviations:** SGRQ, St. George's Respiratory Questionnaire; SRI, Severe Respiratory Insufficiency Questionnaire; NHF, nasal high-flow; NIV, noninvasive ventilation.

[^5]: **Abbreviations:** SAE, serious adverse event; NHF, nasal high-flow; NIV, noninvasive ventilation.
